the close correlation bet ween the two condition s (3) and because allergic rhini tis may be a risk factor for asthma (4) .
Curre ntly BHR can be eva luated thro ugh bron chocon stri ctor stimuli classified as direct (pharmacolog ica l agents such as histam ine or meth acoline ) or indirect (phys iological such as exercise, allergens, ad enosine monoph osphate, hyp erosm olar saline solution and inhaled mannitol dry powder) (5).
Inhaler man nitol dry pow de r, a new indirect osmot ic cha llenge , see ms to have very interestin g and promising perspect ives, especially in paedi atric age, due to its diagnostic speci ficity, high standardiz ation and because it is easy and quick to perform (6) .
The a im of this study is to eval uate the prese nce of BHR w ith the mannitol dry powder cha llenge test in children with intermittent allergic asthma or allergic rhin itis without asthma, who did not res pond to an exe rcise chall enge test (primary endpoint). We also ver ified the possibility to correlate the exhaled nitric ox ide test (FeNO) to a higher risk of BHR (se condary endpoint).
MATERI AL S AND METHODS

Study design
Th e study is a cross-sec tiona l pop ulation study. Fifty children, age d 9-16 years (24 males/26 fem ales), with interm ittent allergi c bron chial asthm a (G roup I -27 subjects), according to GINA guide lines, or with allerg ic rhiniti s without cli nica l man ifestation of asthm a by 2: 12 months (G roup 2 -23 subj ects), were recruited from the Servi zio Autonomo Asma e Fisiopato logia Respiratoria Infantile " Maurizio Mirag lia de l Giudi ce", Departm ent of Paedi atrics, Second Univer sity of Na ples. Dem ograph ic charac teristics of the subj ects are show n in Table I .
All subjects were abl e to run on a treadmill and to carry out a reprod uci ble spirome try and they had undergone a skin prick test in the six months be fore the study. Th e chil dren had not been receiving systemic or inha led ste roids or long-acting p,-agonists for 4 weeks, montelukast and an tihistam ines for 2 weeks and short acting P1-agonists for 48 hours befo re the tests.
All selected patient s performed the following tests on three d ifferent days 2: 48 hour s apart:
Day I: exh aled nitric ox ide (FeN O) det erm ination followed by baseline spirometry and reversibility to inha led pz-ago nists (sa lbutamo l 200 meg MDI + space r, Aerocharnber plu s -Gs k); Day 2: exercise cha llenge test followed by FeNO det erm ination ; Day 3: man nitol powder challenge test followed by FeNO determination .
The study wa s approved by the ethics co mmittee of Seco nd University in Naples and written informe d co nse nt was signed by the children and their parent s andl or legal guardian s.
Lung fu nction test
All subjects were trai ned to perform a co rrec t spiro metry. Lung vo lumes and flow-volume loop s we re evaluated by a Micro lab Viasys spirometer, ca librated eac h mornin g, according to the ATS protocol. Pulm ona ry function was determined as the best result of at least 3/8 acceptab le spi rograms wit h a FVC var iability range :S 10% of each oth er) (7) .
Exercise challenge
The exe rcise challenge test was performed by runni ng on a treadm ill wit h the nose clipped (Pro Form 570) acco rding to the ATS standardized protoco l (8) in an air-c ond itioned roo m with a controlled temp erature (20-25°C) and relati ve humidity (:S 50%).
Baselin e spirometry was performed and the best of three determi nations of FEV I was recorded. Th e heart frequency rate was consta ntly mon itored by a dev ice (Polar T3 1) connected to the ches t of the subject. The test starte d with running at low speed on the treadm ill with a 10% slope. The running spee d was gradually increased to reach approxi mately 90% of the predicted maximum heart rate [(220 -age) x 0.9]. Th is speed was maintained for a maxi mum of 6 min after which the test was inter rupted. FEV I determination was perform ed at I , 5, 10, 15 and 30 minutes a fter the end of the exe rcise. Th e test was co nsidered positive if FEV I decreased 2: 12% fro m baseli ne (1.B.).
Mannitol challenge
Osmohale" kit, packaged in capsul es (cps) co ntaining respectively 0, 5, 10, 20,40 mg of dry powder of manni tol, was used for the challenge test. Th e powder wa s del ivered by Osmohaler" d ispos abl e inhal er device. Th e test was performed as recommended by the distributor (lta lchim ici S.p.A. under exclusive licence.of Pharmaxis Ltd, Sydney, Australia) . Th e dose protocol co nsisted of 0, 5, 10, 20, 40, 80, 160, 160, 160 mg mannitol; the last four doses we re give n in mul tiples of 40 mg cps (9) . The test started with inhalation of the cps°(empty cps acting as a placebo). Subjects were asked to perform , through the device, a maxim al exhalation near to functional residual capacity followed by a maximal inspiration near to total lung capacity; then hold the breath for about 5 seconds. The children had a nose clip during inhalation to reduce as 
Mann itol Challenge Test
• Group 1 • Group 2 much as possible the deposition of mannitol powder in the nasopharynx. Three FEV I measurements were carried out one minute after the end of inhalation and the best value was recorded. The FEV I recorded after inhalation of capsule 0 was used as a reference value (baseline) to determinate the decrease (%) in FEV I in response to the mannitol challenge.
The test was stopped when FEV I decreased 2: 15% (PO 15) vs baseline or 2: 10% after two consecutive doses or when a maximum cumulative dose of 635 mg had been given. For any decrease in FEVI, cumu lative dose/ response ratio was also calculated.
Exhaled nitric oxide (FeND)
The determination of exhaled nrtnc oxide (FeNO) was performed with 'single-breath on line' method by electrochemical analyser (Medisoft -EXPA), according to the European Respiratory Society (ERS) (10) and the American Thoracic Society (ATS) guidelin es (11) .
The patients were instructed to inhale deeply for 2-3 seconds near to the total lung capacity and then to exhale immediately for at least 10 seconds to achie ve reproducible and flat-expiratory plateau. The test was repeated twice more, with an interval of 30 seconds and was considered the average value achie ved from three measurements. Cut-off value of20 ppb was considered.
Statistical analysis
Statistical analysis was performed using SPSS version 18.0 program. Average values, average standard deviations and the geometric average values were determined. Student's paired ttest was used to calculate differences between groups.
Variationswith p :s 0.05 were considered significant.
RESULTS
Fifty subjects were selected; 6 subjects were excluded from the trial because they were positive to exercise challenge test (LB .::::: 12%) and 4 subjects for the onset of persistent cough during the challenge with mannitol dry powder. Forty children (20 with intermittent allergic bronchial asthma and 20 with allergic rhinitis) completed the study.
Lungfunctions test
No statistical differences between groups were observed on baseline spirometry, reversibility to salbutamol (~% FEY1) and exercise challenge test results (LB.) (Table II) .
Mannito l Test
Eighteen subjects of Group I (90%) and 5 subjects of Group 2 (25%) resulted positi ve to mannitol test (Fig. 1) .
Positive mannitol challenge subjects showed no statistically significant differences compared F. DECI:\IO ET AL. (Table III) , but they had significantly higher FeNO values (Fig. 2) .
Mannitol Challenge Test
DISCUSSION
Our study showed that 90% of the subjects with intermittent allergic asthma (Group 1) was positive to the mannitol challenge test, confirming the presence of abnormal lung function in subjects with mild or occasional asthmatic symptoms. In this regard, Horner and colI. have highlighted that , during their growth, asthmatic children show a progressive impro vement of respiratory symptoms, despite persistent deterioration of the lung function, BHR and airways inflammation (12) . Therefore in these subjects, due to. the poor perception of symptoms, the course of the disease and presence of asthma deterioration control markers such as reduction of physical activity, persistent nocturnal dry cough etc., are often underestimated (2) .
This finding is still more surprising if we consider that all of the selected subjects did not respond to an exercise challenge test. A possible explanation could be related to the intrinsic characteristics of the two tests. Mannitol and exercise are' indirect challenges' able to cause an increase in airways osmolarity, with consequent release of mediators such as leukotrienes, prostaglandins, and histamine by inflammatory cells and airway smooth muscle constriction. Thus, the indirect challenge reflects the level of inflammation in the airways (13) . It should be stressed that the intracellular events, occurring during the execution of these tests, are the same whether the increase of airways osmolarity is due to bronchial epithelium dehydration, as in the exercise challenge test, or directly due to a hyperosmolar stimulus like mannitol inhalation. However, as recently demonstrated by Kersten et al. (14) , the main difference between the two tests is represented by the power of the cascade of broncho-obstructive events, which seems to be much greater in the mannitol challenge test compared to the exercise challenge test.
Besides this, the mannitol challenge test seems to represent a viable alternative to the exercise challenge test since it is better reproducible by using a diagnostic protocol which is well standardized, and quick and easy to perform; it does not require specifically trained personnel and does not use expensive equipment such as a treadmill.
As noted by other authors (15) (16) , in our study the mannitol challenge test was well tolerated and there were no significant adverse events, except the onset of a mild cough . Only 4 subjects stopped the challenge test for a very prolonged cough.
We also evaluated the presence of BHR in children with allergic rhinitis without clinical manifestations of asthma for at least 12 months and we demonstrated that 25% of these patients was positive to mannitol challenge. As shown by several epidemiological and pathophysiological studies , this finding confirms that asthma and rhinitis often coexist in the same patient as evidence of a strong relationship between these conditions (3, 17) . In this regard subjects with allergic rhinitis without asthma symptoms had a low FEF 25-75 and an increased bronchial reactivity, both predictive factors of an increased risk of asthma (18) (19) . We verified the possibility to correlate the exhaled nitric oxide test (FeNO) to a higher risk of BHR. As shown in Fig. 2 , the mean baseline FeNO values in the mannitol-positive subjects are significantly higher than in those mannitol-negative. This finding seems to be in accordance with that reported by other authors who demonstrated the presence of a close correlation between FENO values and bronchial hyperresponsiveness to mannitol or methacholine in asthmatic subjects (20) (21) . These observations therefore enhance the hypothesis that a correlation probably exists between the degree of responsiveness to the mannitol challenge test and the level of eosinophilic airway inflammation, as recently demonstrated by Wood et al. (22) .
In conclusion, the mannitol challenge test can be a more useful diagnostic tool than the exercise challenge test to identify BHR in a paediatric population with intermittent allergic asthma or allergic rhinitis because it is better reproducible, quick and easy to perform and well tolerated. Further studies are needed to evaluate in a larger population of asthmatic children the diagnostic validity of the mannitol challenge test and its clinical utility in monitoring the asthma treatment.
